Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Get Free Report) dropped 0.6% during trading on Thursday . The stock traded as low as $90.82 and last traded at $91.12. Approximately 21,979 shares changed hands during mid-day trading, an increase of 80% from the average daily volume of 12,240 shares. The stock had previously closed at $91.69.
Invesco Biotechnology & Genome ETF Stock Performance
The stock has a market capitalization of $287.03 million, a PE ratio of 20.44 and a beta of 0.70. The stock has a 50-day moving average price of $88.17 and a two-hundred day moving average price of $83.30.
Hedge Funds Weigh In On Invesco Biotechnology & Genome ETF
Large investors have recently added to or reduced their stakes in the company. Colonial Trust Advisors purchased a new position in Invesco Biotechnology & Genome ETF during the fourth quarter valued at approximately $25,000. Fifth Third Bancorp bought a new stake in shares of Invesco Biotechnology & Genome ETF during the 1st quarter valued at $30,000. Comerica Bank raised its position in shares of Invesco Biotechnology & Genome ETF by 86.2% during the 4th quarter. Comerica Bank now owns 378 shares of the company’s stock valued at $31,000 after purchasing an additional 175 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Invesco Biotechnology & Genome ETF by 74.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock valued at $40,000 after buying an additional 245 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its stake in shares of Invesco Biotechnology & Genome ETF by 63.2% during the 3rd quarter. NewEdge Advisors LLC now owns 883 shares of the company’s stock valued at $62,000 after buying an additional 342 shares in the last quarter.
About Invesco Biotechnology & Genome ETF
PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
Further Reading
- Five stocks we like better than Invesco Biotechnology & Genome ETF
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Invesco Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.
